Background
Brian Rifkin
Is REACT (Renal Autologous Cell Therapy) the ...

This week, we will discuss the use of renal autologous cell therapy (REACT) in diabetic kidney disease.

Is REACT (Renal Autologous Cell Therapy) the “fifth pillar” in diabetic kidney disease?
Background
Brian Rifkin
2026 KDIGO Anemia Management Guidelines

This week, we will discuss 2026 KDIGO anemia management in patients with kidney disease

2026 KDIGO Anemia Management Guidelines
Background
Cristina Adriana Popa
To INFINITI and Beyond: SGLT2 Inhibitors in ...

This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.

To INFINITI and Beyond: SGLT2 Inhibitors in Kidney Transplant Patients
Background
Cristina Adriana Popa
POTCAST- K+ Pop and Arrhythmia Drop

This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.

POTCAST- K+ Pop and Arrhythmia Drop
Background
Brian Rifkin
A VALIANT effort to combat complement disorders ...

This week, we will discuss the VALIANT study, pegcetacoplan in C3G and IC MPGN.

A VALIANT effort to combat complement disorders with pegcetacoplan

Background

The cause as a cure? The Case for a DDAVP clamp in severe Hyponatremia

The cause as a cure? The Case for a DDAVP clamp in severe Hyponatremia

This week, we will discuss an observational study - a very large series of using DDAVP for treatment of hyponatremia. Yes, you read that right. Read the paper for free thanks to Am J Med and join us on March 27/28 to discuss. 

The Fluid Wars Return: Can we restore Balance to the field

The Fluid Wars Return: Can we restore Balance to the field

March 13/14 we will discuss the pair of trials in NEJM from Vanderbilt: comparing balanced solutions to normal saline in critically ill & not ill patients. Join us for the next #NephJC to parse through SMART & SALT-ED

Kidney Transplant & Race and Ethnicity: Things are Getting Better - Or Are They?

Kidney Transplant & Race and Ethnicity: Things are Getting Better - Or Are They?

This week, we will discuss the JAMA paper on disparities in living donor kidney transplant *rates* across race/ethnicities. There is a parallel paper from the UK, which shows somewhat similar findings. Join us Feb 6 and 7 to discuss on #NephJC!

Will PRESERVE preserve the contrast AKI status quo?

Will PRESERVE preserve the contrast AKI status quo?

This week, we will discuss the fresh-off-the-press NEJM paper on the utility of using NAC (vs placebo) or bicarb-based hydration (vs saline) in preventing contrast AKI. A medical reversal that has taken almost 2 decades...

Longer is Better, Except when it is Not, Really: Hemodialysis Edition

Longer is Better, Except when it is Not, Really: Hemodialysis Edition

The ACTIVE trial tested the hypothesis that longer dialysis would be better for quality of life. Sadly, this did not turn out to be the case. Is the end of longer being better? Join us as we dissect the study at the next NephJC.

IgA Nephropathy: Testing Steroids Again

IgA Nephropathy: Testing Steroids Again

Stop-IgAN suggested steroids may not be useful in patients with intermediate range proteinuria. Now, in a different population with more proteinuria, TESTING finds a mixed result: some benfit + more adverse events. Should we keep on TESTING?